At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

In an interview on treatments following failure of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, Rahul Banerjee, MD outlines the theory behind potential therapeutic strategies ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

At 125 mg palbociclib, two DLTs occurred (grade 3 anemia and grade 3 hypoxia), with no treatment-related deaths; one cerebral hemorrhage death was reported. The LITESPARK-024 trial showed a manageable ...

Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...

According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

The phase 3 IMvigor011 trial represents a landmark shift toward personalized, biomarker-driven adjuvant therapy in muscle-invasive bladder cancer. Gemcitabine-iDRS did not show superior bladder-intact ...

Time to first symptomatic skeletal event, whether including or excluding death, was similar between treatment arms. Most patients did not experience skeletal complications during the follow-up period.

The phase 3 IMvigor011 (NCT04660344) 1 trial, presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, represents a landmark shift toward perso ...

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient ...

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines. Patients with relapsed/refractory ...